Redefining R&D

How Immunoscience is Driving the Pipeline of the Future


Our Latest Stories

Our Science

January 15, 2025

Achieving R&D Excellence to Shape the Medicines of Tomorrow

/assets/dotcom/content-app/events/banner-investors-events_20230703194346.jpg

Fourth Quarter and Full Year 2024 Results

Fourth quarter and full year 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session.

Thursday January 30, 2025
15:00 - 16:30 CET (9:00am – 10:30am EST)

United by Purpose

Each of us plays a unique role in bringing our purpose to life.

About Us

Who We Are

We are an innovative global healthcare company.

Our Pipeline

5

Therapeutic areas

78

Compounds in clinical development

27

Clinical trials in phase 3

Pursue Progress. Discover Extraordinary. 

Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.

Our Latest Press Releases


January 13, 2025
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

January 9, 2025
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

December 23, 2024
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

December 19, 2024
Press Release: Jean-Paul Kress to join Sanofi's Board of Directors